Clinical Trial Update: Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating pembrolizumab with or without maintenance Sac-TMT (MK-2870) in metastatic squamous non-small cell lung cancer is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Sac-TMT (MK-2870) (sacituzumab tirumotecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-small Cell Lung Cancer, NSCLC | Phase 3 | Status: RECRUITING